Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
about
Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerClinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancerInhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitorsDissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the HaystackPI3K mutations in breast cancer: prognostic and therapeutic implicationsRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesPIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical datamRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancerCopy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.PI3K pathway activation results in low efficacy of both trastuzumab and lapatinibA class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expressionManagement of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.PIK3R1 underexpression is an independent prognostic marker in breast cancer.Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancerPrimary trastuzumab resistance: new tricks for an old drug.PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast CancerRole of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.Target points in trastuzumab resistanceEfficacy and tolerability of lapatinib in the management of breast cancerA novel biphenyl urea derivate inhibits the invasion of breast cancer through the modulation of CXCR4Two dimensions in targeting HER2.Trastuzumab: updated mechanisms of action and resistance in breast cancerDiagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerMET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse modelsOvercoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancerAKT signaling in ERBB2-amplified breast cancer.
P2860
Q26775361-E2D7AF30-1F88-4C51-92BC-48B2D4CDBAF1Q27001170-0EBB226C-28FE-4489-8A71-2F43C895EB3BQ27851654-6B26EE5B-D6A8-443A-9570-6339CF217B4EQ27851975-D3B1367B-F962-4AAD-BAB7-B6766D6FFF32Q28067549-8A66365E-0103-4121-9ABC-A429EC13E4FFQ28081992-6A96E6AF-BB41-48B0-8571-6EB7A000DD81Q28083123-CE40A864-E6D3-4E75-A2D9-560C59698924Q28247338-26B2DAA3-BFAA-4602-B33C-A69224EB8491Q28543647-2A17A897-0C21-43F1-AEA8-478FC06B16ACQ31096247-672E0DF7-CE04-49B8-9D7F-FB37CA9B5D52Q33806957-B33508B5-62A1-4A5D-8F97-5D24EEEF45BCQ33864932-CF582B56-E08F-4A69-A5CE-D3DD38268F2CQ33933626-3895B712-B8BB-453D-A884-DC8E4255F1A4Q33991817-51A72C7F-1C84-4A0C-B408-7A1E405976EDQ34241118-5E8BAE04-83E0-4517-AC98-669727F9B132Q34373936-3E0559D9-CEFC-4651-A37E-54AE1A364DA7Q34478129-3B108998-5D96-463E-B856-8BED37709F36Q34570753-3079A637-F601-4C50-9071-68481A391A18Q34610251-6C2D541E-A061-4AE5-83E4-90731D03C073Q34664078-AFAC2D20-ABCA-49DA-BCBA-9A195A60B7B9Q34739677-F17B3F3A-D602-495D-B62D-C74AAE511CD9Q34998509-78FC7EFC-2046-4636-84A8-49CE1519BB53Q35316842-49EB28B3-D2B0-4B3E-968B-18FA366260D5Q35684440-A0A0AF45-6E42-4014-99B3-C050F3B27AE5Q35687465-66612B0E-7C0B-4AF0-AE16-629A8AF1517DQ35821286-79C3D5D6-95B4-4914-B943-DA4074A5D716Q35835926-187E7E65-E957-4A6D-A9F5-F2BD28E9EEFFQ35879531-1E218D7B-F22E-4013-B4E9-7926E6074240Q35895143-53EC5E79-0FB2-4043-9D1C-EDB5F06FEA2EQ36036437-1BAB9794-1695-4459-8F67-37FC252DA591Q36059989-8D1F36E2-2DA3-4660-8D1E-31AE2BD37036Q36064912-5BA43659-3EBC-4A53-9772-199D6800C704Q36117367-F7B7EA2C-F21C-4C47-8B06-2DC5534C8BA4Q36258125-317FF081-EE86-4A90-BBE2-887729580BE2Q36280791-C1BBD76C-51AB-47A7-B955-DE8624A9BE8FQ36295013-5EA43024-168A-4D06-BCA7-E0CA09662BE3Q36361515-6F72C42C-E514-4DDC-8C92-0C60FFC67977Q36408570-2BAEC05A-2120-440A-AD40-6C23B0CF8DD7Q36450457-FF28EB82-DB58-44FB-893C-76E4E9AB32CDQ36563578-EEAEFA1A-AB76-4B9A-959E-467C2BDE880B
P2860
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Association between gain-of-fu ...... fied breast cancer cell lines.
@en
Association between gain-of-fu ...... fied breast cancer cell lines.
@nl
type
label
Association between gain-of-fu ...... fied breast cancer cell lines.
@en
Association between gain-of-fu ...... fied breast cancer cell lines.
@nl
prefLabel
Association between gain-of-fu ...... fied breast cancer cell lines.
@en
Association between gain-of-fu ...... fied breast cancer cell lines.
@nl
P2093
P2860
P356
P1433
P1476
Association between gain-of-fu ...... fied breast cancer cell lines.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDP304
P577
2009-07-24T00:00:00Z